Abliva AB (publ) (ABLI.ST)
Abliva AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SE. The stock last traded at $0.44, up 0.23% on the session, giving a market capitalisation of $715.7M. Its beta of 0.75 implies it has historically moved less than the broad market.
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Abliva AB (publ) is most often compared with the following Healthcare names: